PHILADELPHIA–(BUSINESS WIRE)–CLEU Diagnostics, the company reimagining comprehensive clinical laboratory testing has expanded its commercial advisory board with the additions of Jill Thompson and Harold Kisner PhD, MBA. Ms. Thompson and Dr. Kisner combined have five decades of experience in commercializing first-in-kind diagnostic technology.
Ms. Thompson is the principal at JoLT Group, a consulting practice focused on the Life Sciences and Diagnostics where she spent years leading teams through startups, turnarounds, product development and commercialization. Her extensive rolodex of strategics, investment bankers, industry analysts, and key opinion leaders has led to multiple licensing deals, joint ventures, and mergers and acquisitions. “LabSimple checks all the boxes and is really a culmination of what we as an industry have been hoping to achieve for a long time.”, said Ms. Thompson.
Dr. Kisner is an accomplished strategic leader and company builder with significant experience in the laboratory diagnostics industry. As a nationally recognized expert in clinical laboratory operations and workflow automation, Dr. Kisner brings deep domain expertise to integrated health systems, academic medical centers, and large physician group practices across the U.S. He previously served as Chief Operating Officer and Laboratory Director for Path Lab Inc, one of the fastest growing integrated health network laboratories, as well as Chief Laboratory Officer for Davita Laboratories. “The remarkable capability of LabSimple makes it possible to introduce extremely advanced laboratory techniques into any market that would usually only be possible with large expensive purpose-built instruments. This is an exciting advancement for our industry, as it enables numerous applications that were previously not thought to be possible for a point of care style device.”, said Dr. Kisner.
About LabSimple
LabSimple is a next generation point-of-care style diagnostic platform designed as an all-in-one replacement for the clinical laboratory while being simple enough for anyone to use without training. LabSimple is disruptive because it has the unusual combination of being comprehensive, high performance, simple, and low cost.
About CLEU Diagnostics
CLEU Diagnostics was founded in 2018 by a group of renowned physicians with the goal of transforming healthcare through innovation. LabSimple is a disruptive, next generation technology that will redefine the $110B US clinical lab testing market.
Visit us at www.cleudx.com
Contacts
Investor and Media Inquiries
[email protected]
